Strides Arcolab receives ANDA approval for Famotidin Injection

New Delhi, Jun 26 (UNI) Strides Arcolab, one of the country's emerging pharma companies, today said it has received Abbreviated New Drug Application (ANDA) approvals for Famotidin Injection USP 10 mg/ml - 2 mL, 4 mL and 20 mL.

The product is licenced to Akorn-Strides, LLC, which is a joint venture formed in 2004 by Akorn Inc and Strides Arcolab, the company said in a statement.

The Akorn-Strides partnership now has nine ANDA approvals for sterile injectable products and commercialisation is expected to commence shortly, it added.

Strides has 14 manufacturing plants spread across the Brazil, Mexico, Italy, Poland, Singapore and India.

UNI SG RAR SSC1336